VigRX Plus is the result of collaboration between herbal scientists, medical consultants, and nutraceutical engineers.

Comment from CEO Yoshiyuki Aikawa “We are delighted to welcome Mr. Shinya Inoue as our new CMO. He brings exceptional ...

Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global ...

Customers at Fred Meyer’s 60 pharmacies in Washington now have access to free locking bags to more safely store their opioid prescriptions. The Washington State Health Care Authority (HCA) is ...

Further details of the domestication will be disclosed on a Current Report on Form 8-K that will be filed with U.S. Securities and Exchange Commission (the "SEC") on the Company's website and at ...

Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy En cliquant sur ce lien, vous acceptez l'utilisation de cookies sur ce site internet.

Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic ...

Direct Meds LLC, a fast-scaling telemedicine provider serving the U.S. and Canada, today announced a company-wide deployment of artificial intelligence (AI) technologies to ensure scalable, efficient ...

The Digital Health Awards celebrates the best digital health resources developed for consumers and healthcare professionals. Visory Health was recognized as a digital resource that is redefining ...

PCS11T: PCS11T is Processa’s preclinical oncology asset based on the active metabolite of irinotecan. The company continues to define and explore preclinical and clinical development strategies as ...

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publication of initial clinical results using the MAGiC ...

The Company notes that the Dogecoin Protocol remains under development, and there can be no assurance regarding its completion, features, or timing of deployment.